Three-Pronged attack on aggressive breast cancer before surgery

This study is testing a new three-drug combination given before surgery for early-stage triple-negative breast cancer (TNBC), an aggressive type. The goal is to see if adding two newer drugs (sintilimab and anlotinib) to standard chemotherapy can better shrink or eliminate the tumor before it is surgically removed. Researchers will measure if the tumor disappears completely under the microscope after treatment and monitor patients for side effects and long-term outcomes.